Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Up 92.2% in January

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 154,900 shares, a growth of 92.2% from the January 15th total of 80,600 shares. Based on an average daily volume of 366,900 shares, the days-to-cover ratio is presently 0.4 days. Currently, 8.9% of the shares of the stock are sold short.

Institutional Investors Weigh In On Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC bought a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned about 1.17% of Avenue Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 17.34% of the company’s stock.

Avenue Therapeutics Stock Down 3.6 %

ATXI stock opened at $1.32 on Thursday. The company has a fifty day simple moving average of $1.72 and a two-hundred day simple moving average of $2.14. The firm has a market capitalization of $2.71 million, a P/E ratio of 0.07 and a beta of -0.28. Avenue Therapeutics has a 52 week low of $1.22 and a 52 week high of $15.00.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.